CHRS

Q: What is the price of Coherus BioSciences (CHRS) today?

The price of Coherus BioSciences (CHRS) today is $ 1.73, with return of 121.28% compared to the last year. The price of Coherus BioSciences (CHRS) started the year trading around $ 1.42 and today it is at $ 1.73. Follow the real-time price chart, the historical price of Coherus BioSciences (CHRS) and international markets.

Q: When does Coherus BioSciences (CHRS) pay dividends?

Coherus BioSciences (CHRS) did not distribute dividends in the last year.

Q: Is Coherus BioSciences (CHRS) worth it?

Currently, Coherus BioSciences (CHRS) is priced at $ 1.73, with a P/E of 1.24%, representing a deviation of 90% from its historical average P/E. In the last year, the stock showed a variation of 121.28 in its price and distributed $ 0.00 in dividends, resulting in a Dividend Yield of 0.00%. The total shareholder return was 121.28%.It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

Q: How can I buy Coherus BioSciences (CHRS) stock?

Investing in stocks of Coherus BioSciences (CHRS) can be done in two ways: by buying the stock abroad. The stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

Q: How much would 100 shares of Coherus BioSciences (CHRS) yield today?

The yield of Coherus BioSciences (CHRS) was -1.70% in the last month, 121.28% in the last year and -87.68% in the last 5 years (already considering appreciation and dividends).In the last 12 months, the company paid a total of $ 0.00 in dividends, with a Dividend Yield of 0.00%.If you wanted to buy 100 stocks of Coherus BioSciences (CHRS) today, the total investment would be $ 173.00, based on the current price of $ 1.73.If past performance were to repeat, the return on your investment would be:In 1 year: $ 382.81In 5 years: $ 21.31In 10 years: $ 13.29It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

Coherus BioSciences Inc.

Price

$ 1.73

return (12m)

121.28%

p/e

1.24

p/bv

3.40

DIVIDEND YIELD

0.00%

CHRS price

CHRS

If you had invested

years ago

7 days

30 days

6 months

YTD

1 year

5 years

10 years

ago, you would now have *

ago, you would now have:

*The figure considers the reinvestment of dividends.

Return on Investment CHRS

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-1.70%

3 months

26.28%

1 year

121.28%

2 years

-25.75%

5 years

-87.68%

10 years

-92.32%

Fundamentals CHRS

review the fundamentals of Coherus BioSciences shares

P/E

1.24

Sector: -5.82 Industry: -5.82

P/S (PSR)

4.92

Sector: -4.74 Industry: -4.74

P/BV

3.40

Sector: 1.40 Industry: 1.40

DIVIDEND YIELD (DY)

0.00%

Sector: - Industry: -

ROA

65.04%

Sector: -72.38% Industry: -72.38%

ROE

275.41%

Sector: -84.15% Industry: -84.15%

ROIC

-258.91%

Sector: -1,194.38% Industry: -1,194.38%

NET MARGIN

100.00%

Sector: -46.16% Industry: -46.16%

GROSS MARGIN

67.25%

Sector: 35.92% Industry: 35.92%

OPERATING MARGIN

-100.00%

Sector: -46.05% Industry: -46.05%

EV/EBITDA

-1.22

Sector: -5.52 Industry: -5.52

EV/EBIT

-1.19

Sector: -5.77 Industry: -5.77

PRICE-TO-ASSETS

0.80

Sector: 1.13 Industry: 1.13

BVPS

0.51

Sector: 1.63 Industry: 1.63

EPS

1.40

Sector: -2.73 Industry: -2.73

EQUITY-TO-ASSETS RATIO

0.24

Sector: 0.32 Industry: 0.32

LIABILITIES / ASSETS

0.76

Sector: 0.33 Industry: 0.33

CAGR REVENUE 5 YEARS

-33.59%

Sector: - Industry: -

CAGR PROFIT 5 YEARS

0.00%

Sector: - Industry: -

FAIR VALUE OF Coherus BioSciences ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$ 1.73

Fair Value

$ 0.00

Upside/Downside Return potential.

131.68%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals CHRS

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/bv	ROE	dy	market cap	net margin
JNJ	21.84	7.39	33.81%	2.14%	$ 585.48 B	28.46%
PFE	20.72	1.73	8.35%	6.07%	$ 161.03 B	12.42%
ABBV	87.32	0.00	0.00%	3.18%	$ 369.02 B	6.91%
NVO	10.48	5.40	51.50%	4.56%	$ 164.23 B	33.05%
MRK	16.43	0.00	0.00%	2.71%	$ 300.00 B	28.08%
AZN	30.87	6.48	20.99%	1.57%	$ 315.61 B	17.41%
GILD	20.39	7.67	37.62%	2.28%	$ 173.52 B	28.90%
BMY	17.20	-3.56	-20.72%	4.18%	$ 121.35 B	14.64%
ZTS	19.33	15.51	80.25%	1.72%	$ 51.66 B	28.23%
REGN	17.42	2.51	14.41%	0.47%	$ 78.47 B	31.41%
HALO	24.01	155.91	649.21%	0.00%	$ 7.61 B	22.69%
AMGN	24.32	21.66	89.06%	2.78%	$ 187.54 B	20.98%
MCK	25.06	-1,098.65	-4,383.84%	0.36%	$ 108.77 B	1.09%
VRTX	28.19	5.97	21.18%	0.00%	$ 111.43 B	32.94%
CAH	30.39	-18.71	-61.56%	0.95%	$ 50.52 B	0.68%
ADMA	14.89	4.58	30.78%	0.00%	$ 2.19 B	28.80%
BIIB	20.16	1.43	7.08%	0.00%	$ 26.07 B	13.07%
HRMY	9.96	1.82	18.24%	0.00%	$ 1.58 B	18.27%

Stock vs Indice Comparison Tool

If you had invested (change) 2 years years ago, ago, you would now have

R$ 1.000,00 in PETR4 You would now have R$ 2.294,60

R$ 1.000,00 in LEVE3 You would now have R$ 5.240,60

*The value considers the reinvestment of dividends.

CHRS Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Coherus BioSciences

Coherus BioSciences Inc.

Average Investor10 user rating

4.0 (1 people)

United States

16 years

Founded: 2010

2014

Time since IPO - 12 years

291

Employees

The Company Coherus BioSciences Inc. (United States), is listed on Nasdaq with a market value of $ 207.60 Millions, having an equity of $ 61.01 Millions.

With a total of 291 employees, the company is listed in the sector of Health Care and categorized in industry of Biotechnology.

In the last 12 months the Company had a revenue of $ 42.17 Millions, which generated a loss in the amount of $ 168.03 Millions.

As for its main indicators, the Company has a P/E ratio of 1.24, a P/BV ratio of 3.40 and in the last 12 months the Company did not pay dividends.

The Company is traded internationally through the ticker CHRS.

Market cap

$ 207.60 Millions

Net worth

$ 61.01 Millions

US$ 61,010,000.00

Assets

$ 258.34 Millions

US$ 258,340,000.00

Total Shares Outstanding

120.00 Millions

120,000,000

Average Daily Trading Volume

$ 2.40 Millions

US$ 2,402,758.80

Sector

Health Care

Industry

Biotechnology

CHRS

CHRS revenue and profits

Financial Results CHRS

DRAG THE FRAME TO SEE MORE DATA

CHRS cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more stocks

BFRA - Biofrontera

$ - -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$ 884.28 29,96% (12M)

P/E

25.06

0.36%

ROE

-4,383.84%

P/BV

-1,098.65

CAH - Cardinal Health

$ 214.05 67,60% (12M)

P/E

30.39

0.95%

ROE

-61.56%

P/BV

-18.71

JNJ - Johnson & Johnson

$ 243.04 63,02% (12M)

P/E

21.84

2.14%

ROE

33.81%

P/BV

7.39

PFE - Pfizer

$ 28.32 32,24% (12M)

P/E

20.72

6.07%

ROE

8.35%

P/BV

1.73

ABBV - AbbVie

$ 208.84 16,32% (12M)

P/E

87.32

3.18%

ROE

0.00%

P/BV

0.00

MRK - Merck & Co.

$ 120.87 55,08% (12M)

P/E

16.43

2.71%

ROE

0.00%

P/BV

0.00

AZN - AstraZeneca

$ 203.49 57,42% (12M)

P/E

30.87

1.57%

ROE

20.99%

P/BV

6.48

BFRA - Biofrontera

$ - -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$ 884.28 29,96% (12 M)

P/L

25.06

0.36%

ROE

-4,383.84%

P/VP

-1,098.65

CAH - Cardinal Health

$ 214.05 67,60% (12 M)

P/L

30.39

0.95%

ROE

-61.56%

P/VP

-18.71

JNJ - Johnson & Johnson

$ 243.04 63,02% (12 M)

P/L

21.84

2.14%

ROE

33.81%

P/VP

7.39

PFE - Pfizer

$ 28.32 32,24% (12 M)

P/L

20.72

6.07%

ROE

8.35%

P/VP

1.73

ABBV - AbbVie

$ 208.84 16,32% (12 M)

P/L

87.32

3.18%

ROE

0.00%

P/VP

0.00

MRK - Merck & Co.

$ 120.87 55,08% (12 M)

P/L

16.43

2.71%

ROE

0.00%

P/VP

0.00

AZN - AstraZeneca

$ 203.49 57,42% (12 M)

P/L

30.87

1.57%

ROE

20.99%

P/VP

6.48

Frequently Asked Questions

What is the price of Coherus BioSciences (CHRS) today?

The price of Coherus BioSciences (CHRS) today is $ 1.73, with return of 121.28% compared to the last year. The price of Coherus BioSciences (CHRS) started the year trading around $ 1.42 and today it is at $ 1.73. Follow the real-time price chart, the historical price of Coherus BioSciences (CHRS) and international markets.

When does Coherus BioSciences (CHRS) pay dividends?

Coherus BioSciences (CHRS) did not distribute dividends in the last year.

Is Coherus BioSciences (CHRS) worth it?

Currently, Coherus BioSciences (CHRS) is priced at $ 1.73, with a P/E of 1.24%, representing a deviation of 90% from its historical average P/E. In the last year, the stock showed a variation of 121.28 in its price and distributed $ 0.00 in dividends, resulting in a Dividend Yield of 0.00%. The total shareholder return was 121.28%.

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

How can I buy Coherus BioSciences (CHRS) stock?

Investing in stocks of Coherus BioSciences (CHRS) can be done in two ways: by buying the stock abroad. The stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.

BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

How much would 100 shares of Coherus BioSciences (CHRS) yield today?

The yield of Coherus BioSciences (CHRS) was -1.70% in the last month, 121.28% in the last year and -87.68% in the last 5 years (already considering appreciation and dividends).

In the last 12 months, the company paid a total of $ 0.00 in dividends, with a Dividend Yield of 0.00%.

If you wanted to buy 100 stocks of Coherus BioSciences (CHRS) today, the total investment would be $ 173.00, based on the current price of $ 1.73.

If past performance were to repeat, the return on your investment would be:

In 1 year: $ 382.81
In 5 years: $ 21.31
In 10 years: $ 13.29

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

CHRS

Coherus BioSciences Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment CHRS

review the fundamentals of Coherus BioSciences shares

P/E

P/S (PSR)

P/BV

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

NET MARGIN

GROSS MARGIN

OPERATING MARGIN

EV/EBITDA

EV/EBIT

PRICE-TO-ASSETS

BVPS

EPS

EQUITY-TO-ASSETS RATIO

LIABILITIES / ASSETS

CAGR REVENUE 5 YEARS

CAGR PROFIT 5 YEARS

Graham's Fair Value

If you had invested (change) 2 years years ago, ago, you would now have

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Coherus BioSciences

Coherus BioSciences Inc.

United States

16 years

2014

291

PROFIT X PRICE CHRS

Financial Results CHRS

CHRS cash flow

Asset, Revenue and Profit Growth - CHRS

CHRS balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

PFE - Pfizer

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

PFE - Pfizer

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

Frequently Asked Questions